Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Open accessPublished version of a preprint
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Impacts of vaccine prioritization strategies on mortality and infections. (A) Distribution of vaccines for five prioritization strategies: under 20 years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all ages. (B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of the total population infected over time and [(F) and (G)] cumulative mortality for no vaccines (gray dashed lines) and for five different prioritization strategies [colored lines matching (A)], with [(B) and (F)] 10% and [(C) and (G)] 30% vaccine supply. (D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak for vaccine supplies between 1 and 50% after 365 days of simulation. Squares and diamonds show how the outputs from single simulations [(F) and (G)] correspond to points in summary curves (H). Gray shading indicates the period during which vaccine is being rolled out at 0.2% of total population per day. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. These simulations assume contact patterns and demographics of the United States (38, 53) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).](https://figures.cochat.ai/paper-figures/040af1c419fe4105805e757ba6eecdfa/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-1.jpg)
![Fig. 2 Mortality-minimizing vaccine prioritization strategies across reproductive numbers R0 and countries. (A to E) Heatmaps show the prioritization strategies that result in maximum reduction of mortality for varying values of [(A) and (B)] the basic reproductive number R0 and [(C), (D), and (E)] across nine countries, for vaccine supplies between 1 and 50% of the total population, for an all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy. [(A) and (B)] Contact patterns and demographics of the United States (38, 53). [(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, India; USA, United States of America; and BEL, Belgium, with R0 and rollout speeds as indicated.](https://figures.cochat.ai/paper-figures/3232e6d2c98d4491b422e996e35f7beb/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-2.jpg)
![Fig. 3 Effects of age-dependent vaccine efficacy on the impacts of prioritization strategies. (A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, beginning at age 60 (dashed line). (B and C) Percent reduction in deaths in comparison with an unmitigated outbreak for transmission-blocking all-or-nothing vaccines with either constant 90% efficacy for all age groups (solid lines) or age-dependent efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)]. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. Shown are contact patterns and demographics of the United States (38, 53); all-or-nothing and transmission-blocking vaccine.](https://figures.cochat.ai/paper-figures/85e54e74290b4a1b82ec5b49b5f8d03f/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-3.jpg)
![Fig. 4 Effects of existing seropositivity on the impacts of prioritization strategies. (A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of life lost (YLL) for prioritization strategies when existing age-stratified seroprevalence is incorporated [August 2020 estimates for New York City; mean seroprevalence 26.9% (28)]. Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), and approximately 3 months of seroreversion (supplementary materials, materials and methods) (29). Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing and transmission-blocking vaccine with 90% vaccine efficacy. Lower and higher seroprevalence examples are provided in figs. S12 and S13, respectively.](https://figures.cochat.ai/paper-figures/4122f4138dc44271af1ce6fd7d40abb0/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaccination alone is not expected to be able to control the spread of the infection, and a carefully planned vaccination campaign25,26 needs to be coordinated with continued implementation of NPIs27 until sufficient coverage is reached to make the case fatality rate (CFR) similar to that of seasonal influenza.”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
COVID-19 and Racial/Ethnic Disparities
Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020) · JAMA · doi:10.1001/jama.2020.8598 · Cited by 2,047 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,759 · cited 1×
“Age-stratified susceptibility values were drawn from literature estimates ( 13 ).”
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2700-3 · Cited by 1,459 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S., Viboud, C., Vespignani, A., et al. (2020) · Science · doi:10.1126/science.abb8001 · Cited by 1,107 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100 · cited 1×
“COVID-19 vaccines may not be equally effective across age groups in preventing infection or transmission, a phenomenon known to affect influenza vaccines ( 23–26 ).”
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · cited 2×
“Serostatus itself is an imperfect indicator of protection, and the relationship of prior infection, serostatus, and protection may change over time (10, 29,32,33).”
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Research works printed but not linked: 1
- K. E. Atkinson An Introduction to Numerical Analysis (Wiley 1989) chap. 2 pp. 56–58 second edn.
Cited by
Items 601–700 of 777
Young, B. R., Ho, F. C. S., Lin, Y., Lau, E. H. Y., Wu, P., Cowling, B. J., & Tsang, T. K. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102972 · Cited by 1
Inmunidad y vacunación contra la covid-19
Anaya, J., González, J. M., Villalba-Vizcaíno, V., Grajales, P. J. P., Rengifo, C., Trillos, C., & Gamboa, L. F. (2021) · Medicina · doi:10.56050/01205498.1558 · Cited by 1
Spitzer, M. (2021) · Nervenheilkunde · doi:10.1055/a-1298-1189 · Cited by 1
“In Polen, China, Spanien, den USA und Belgien hingegen reduziert das Impfen der Menschen im Alter zwischen 20 und 49 Jahren die Sterblichkeit am besten [38]9.”
BackgroundInfluentialOptimal piecewise constant vaccination and lockdown policies for COVID-19Preprint
Salcedo-Varela, G. A., Peñuñuri, F., González‐Sánchez, D., & Díaz‐Infante, S. (2021) · medRxiv · doi:10.1101/2021.01.13.21249773 · Cited by 1
Hunziker, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3780070 · Cited by 1
COVID-19 epidemic scenarios into 2021 based on observed key superspreading eventsPreprint
Santana-Cibrian, M., Acuña‐Zegarra, M. A., Rodríguez, C. E., Mena, R. H., & Velasco‐Hernández, J. X. (2021) · medRxiv · doi:10.1101/2021.04.14.21255436 · Cited by 1
COVID-19 Sex-Age Mortality Modeling - A Use Case of Risk-Based Vaccine PrioritizationPreprint
Shapiro, V. (2021) · SocArXiv (OSF Preprints) · doi:10.31235/osf.io/5c8bd · Cited by 2
Transmission Dynamics of COVID-19 Pandemic Non-pharmaceutical Interventions and VaccinationPreprint
Wang, B.-G., Huang, S., Xiong, Y., Xin, M.-Z., Li, J., Zhang, J., & Ma, Z. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2107.02962 · Cited by 1
“In consideration of limited initial supply of SARS-CoV-2 vaccine, Bubar et al. [2] used a mathematical model to compare five age-stratified prioritization strategies.”
MethodGoldstein, J. R., Cassidy, T., & Wachter, K. W. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107654118 · Cited by 1
ExPrt: An Explainable Spatio-Temporal Framework for Prioritizing the COVID-19 Vaccination in IndiaPreprint
Khan, A., & Ghosh, S. K. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3909772 · Cited by 1
Bolton, L. (2022) · OpenDocs (Institute of Development Studies) · doi:10.19088/cc.2021.007 · Cited by 1
Impact of Prioritizing Elderly and High-risk Individuals During COVID-19 Vaccine AllocationPreprint
Oruc, B. E., Fujimoto, A. B., Breiman, R. F., & Keskinocak, P. (2021) · Research Square · doi:10.21203/rs.3.rs-944201/v1 · Cited by 1
Li, Z., Wang, J., Yang, B., Li, W., Xu, J., & Wang, T. (2021) · medRxiv · doi:10.1101/2021.10.27.21265522 · Cited by 1
“For example, evidences showed that prioritizing the 20‒49 age group and adults greater than 65 years old can reach the least infections and deaths respectively[19].”
BackgroundInfluentialPandemic escape plan: Discontinuing policies that have reached their expiry date
van Zyl, G. U., Dramowski, A., & Preiser, W. (2022) · South African Medical Journal · doi:10.7196/samj.2022.v112i3.16381 · Cited by 1
Mahajan, A., Sivadas, N., & Panda, P. (2022) · doi:10.36227/techrxiv.17705957.v1 · Cited by 1
Liu, D., Tse, C. K., Chan, R. H. M., & Zhan, C. (2021) · medRxiv · doi:10.1101/2021.05.10.21256999 · Cited by 1
Paris, C. F., Spencer, J. A., Castro, L. A., & Valle, S. Y. D. (2022) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · doi:10.2172/1874147 · Cited by 1
Anupong, S., Chantanasaro, T., Wilasang, C., Jitsuk, N. C., Sararat, C., Sornbundit, K., Pattanasiri, B., Chadsuthi, S., & Modchang, C. (2022) · medRxiv · doi:10.1101/2022.08.05.22278489 · Cited by 1
“fSD Proportion of symptomatic infected individuals who eventually die See supplementary [20]”
BackgroundMcLaren, Z. M. (2023) · medRxiv · doi:10.1101/2023.01.12.23284481 · Cited by 1
Data science for epidemiology: a case study of dengue in Brazil.
Roster, K. I. O. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.55.2022.tde-27022023-142607 · Cited by 2
Inferring vaccine efficacy and mode of action from human challenge studiesPreprint
Miura, F., Klinkenberg, D., Ainslie, K. E. C., Backer, J. A., Leung, K. Y., McDonald, S., de Boer, P., & Wallinga, J. (2023) · medRxiv · doi:10.1101/2023.09.24.23296054 · Cited by 1
Larsen, S. L., & Kraay, A. N. M. (2024) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2023.2273 · Cited by 1
“Optimalcontrolstrategies can depend on whether transmission, healthcare capacity or mortality is being targeted (e.g. [9,10]).”
BackgroundResource Allocation in Contagious NetworksPreprint
Zhang, Y., Dong, L., & Hu, M. X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4814803 · Cited by 1
Resource Allocation: Justice and Resource Allocation in Public Health
Rhodes, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00310-0 · Cited by 1
Nande, A., Larsen, S. L., Turtle, J., Davis, J. T., Bandekar, S. R., Lewis, B. L., Chen, S., Contamin, L., Jung, S.-M., Howerton, E., et al. (2026) · medRxiv · doi:10.64898/2026.04.07.26349269 · Cited by 1
Vaccine Technologies Jockey for Primacy in Pandemic Response
Dolgin, E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.010
del Río, C., & Omer, S. B. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4623
Liu, D., Tse, C. K., Chan, R. H. M., & Zhan, C. (2021) · Research Square · doi:10.21203/rs.3.rs-590770/v1
Developing and validating an individual-level risk calculator for COVID-19 in the United StatesPreprint
Hu, X. C., Starling, J. E., Lipman, E., & Pendl-Robinson, E. L. (2021) · Research Square · doi:10.21203/rs.3.rs-456971/v1
Chawla, V., Kaur, A., Kaur, A., Singh, K., Sidhu, S. K., & Nagpal, N. (2021) · Indian Journal Of Applied Research · doi:10.36106/ijar/3907443
McAlister, F. A., Bushnik, T., Leung, A. A. C., & Saxinger, L. M. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.210529-f
Hartnett, G. S., Parker, E., Gulden, T. R., Vardavas, R., & Kravitz, D. W. (2021) · RAND Corporation eBooks · doi:10.7249/wra1068-1
Zhou, D., Shao, T., Liu, Z., Pan, X., Zhang, X., Zhou, C., & Tang, W. (2021) · Research Square · doi:10.21203/rs.3.rs-789689/v1
Hunziker, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3794249
Evaluating the Impact of Vaccination on COVID-19 Using Model Checking
Li, X. (2021) · Proceedings/Proceedings of the ... International Conference on Software Engineering and Knowledge Engineering · doi:10.18293/seke2021-131
epimargin: A Toolkit for Epidemiological Estimation, Prediction, and Policy Evaluation
Soman, S., Loftus, C., Buschbach, S., Phadnis, M., & Bettencourt, L. M. A. (2021) · The Journal of Open Source Software · doi:10.21105/joss.03464
“Attempts to use a compartmental model to drive policy decisions often treat the systems under study as deterministic and vary parameters such as the reproductive rate across a range deemed appropriate by the study authors (Bubar et al., 2021).”
MethodDelva, W., Dominic, E. M., Beauclair, R., Ouifki, R., Kroon, M., Volmink, H., & Dorkin, E. (2021) · medRxiv · doi:10.1101/2021.09.06.21263151
Hierarchical Model of Multi-level Index to Assess Local Resilience Capability in COVID-19Preprint
Deng, Q., Luo, L., Zhang, H., Chen, T., Wang, Y., Wang, X., Wang, W., Li, Q., & Niu, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-900502/v1
Franco, J. E. M. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/174883 · Cited by 1
Evaluation of the United States COVID-19 Vaccine Allocation StrategyPreprint
Islam, M. R., Oraby, T. F., McCombs, A., Chowdhury, M. M., Al-Mamun, M., Tyshenko, M. G., & Kadelka, C. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3869650
Observación del plan de vacunación del COVID-19 en Colombia
Pinzón, J. E. D. (2021) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1273
Esquemas completos aplicados contra COVID-19 priorizados por entidad territorial en Colombia
Pinzón, J. E. D. (2021) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1262
Pros and cons of repository injection therapy in the practice of allergy.
Prigal, S. J., Wb, S., Naterman, H. L., Furstenberg, F. F., Gaillard, G. E., Mitchell, W. F., BROWN, F. R., & Schaffer, N. (1963) · PubMed
COVID-19 Vaccines – What are Known? What are not yet known?
Loh, J., & Yew, W. S. (2021) · The Singapore Family Physician · doi:10.33591/sfp.47.7.uo2
Evaluation of the effects of vaccination regimes on the transmission dynamics of COVID-19 pandemicPreprint
Nakamoto, I., Zhang, J., Zhuang, W., & Guo, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1279130/v1
Optimal vaccination with time-varying based on immunity barrier in Hunan Province, ChinaPreprint
Guo, X., Liu, Z., Yang, S., Zhao, Z., Guo, Y., Abudurusuli, G., Rui, J., Wang, Y., Zhao, S., Ge, Z., et al. (2022) · medRxiv · doi:10.1101/2022.03.02.22271610
“Depending on the objectives, several studies have suggested that priority should be given to vaccinating the elderly population against the new coronavirus to reduce the number of seriously ill patients and reduce mortality, and to the young population to reduce the spread of the new coronavirus[12, 13].”
BackgroundCOVID-19 AŞISI ÇİZELGELEME PROBLEMİ: TERMAL NAKLİYE KONTEYNERLERİ UYGULAMASI
Çoban, E. (2022) · Endüstri Mühendisliği · doi:10.46465/endustrimuhendisligi.987677
Adverse effects of vaccinations and potential therapies against COVID-19
Wasiak, K., & Rieske, P. (2022) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2022.114392
Mahajan, A., Sivadas, N., & Panda, P. (2022) · doi:10.36227/techrxiv.17705957
Prioritizing COVID-19 Vaccine Delivery for the Indian Population
Singh, M., Modak, S., & Sarkar, D. (2022) · International Journal of Software Innovation · doi:10.4018/ijsi.301228
Modeling, Estimation, and Optimal Control of Anti-COVID-19 Multi-dose Vaccine AdministrationPreprint
Scarabaggio, P., Carli, R., Cavone, G., Epicoco, N., & Dotoli, M. (2021) · doi:10.36227/techrxiv.16794724.v1
Modeling, Estimation, and Optimal Control of Anti-COVID-19 Multi-dose Vaccine AdministrationPreprint
Scarabaggio, P., Carli, R., Cavone, G., Epicoco, N., & Dotoli, M. (2021) · doi:10.36227/techrxiv.16794724
A stochastic model for COVID-19 with a highly effective vaccine
Nsuami, M. U., & Witbooi, P. J. (2021) · Journal of Mathematical and Computational Science · doi:10.28919/jmcs/6331
Modelling the Impact of Delaying Vaccination Against SARS-CoV-2 Assuming Unlimited Vaccines SupplyPreprint
Massad, E., Amaku, M., Covas, D. T., Coutinho, F. A. B., & Azevedo, R. S. (2021) · Research Square · doi:10.21203/rs.3.rs-605245/v1
Coronaviruses Research in BRICS Countries
Fielding, B. C., & Schäfer, G. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-4027-6
Modeling vaccine allocation and equity implications of COVID-19 containment strategiesPreprint
Nakamoto, I., & Zhang, J. (2022) · medRxiv · doi:10.1101/2022.09.05.22279623
“To account for prospective diversified scenarios of transmission in practice, we additionally incorporate three cases where: (1) transmission risk in HAS and LAS is at commensurate levels; (2)transmission risk of HAS is more severe; (3)transmission risk of LAS is more severe.”
BackgroundMethodGaie, C., & Mueck, M. (2022) · Studies in computational intelligence · doi:10.1007/978-3-031-04597-4_11
The Role of Memory T Cells in Controlling the Covid-19 Pandemic
Kusmardi, K., Ramadhian, D., Pratomo, I. P., & Tedjo, A. (2021) · Majalah Patologi Indonesia · doi:10.55816/mpi.v30i2.476
“…yang akan divaksin mirip dengan India yaitu vaksinasi pada tenaga medis dan pekerja fontliner, hanya saja pada kelompok usia 18-59 tahun.14 Hal yang perlu menjadi perhatian pada pemodelan menurut Bubar et al (2021) tersebut adalah terdapat asumsi terkait efektivitas vaksin yaitu penurunan antibodi.”
BackgroundHasan, A., Hummadi, S., Sadkhan, R., & Ali, M. M. (2022) · kufa journal for nursing sciences · doi:10.36321/kjns/2022/120123
Layered vaccine allocation for spatio-temporal vaccination of COVID-19
Ghazal, I., Rachadi, A., & Hamid Ez-zahraouy, A. (2022) · International Journal of Modern Physics C · doi:10.1142/s0129183123500420
COVID-19 Double-Decrement Model Forecasting for South Korean Population
Chandra, C. E., & Abdullah, S. (2022) · International Journal on Advanced Science Engineering and Information Technology · doi:10.18517/ijaseit.12.4.15698
„Paszporty covidowe” nie są i nie mogą być uwarunkowane jedynie względami medycznymi
Rieske, P. (2022) · Wydawnictwo Naukowe Instytutu na rzecz Kultury Prawnej Ordo Iuris eBooks · doi:10.37873/oipress.37.45
Nakamoto, I., Zhang, J., Zhuang, W., & Chen, W. (2022) · doi:10.2196/preprints.43732
Kakaï, R. G., & Tovissodé, C. F. (2022) · Preprints.org · doi:10.20944/preprints202212.0067.v1
Acuña‐Zegarra, M. A., Santana-Cibrian, M., Hernandez-Vela, C. E. R., Mena, R. H., & Velasco‐Hernández, J. X. (2022) · medRxiv · doi:10.1101/2022.12.19.22283668
“The transmission dynamics has been described with many different methodologies, several of them centered on estimating the effective reproduction number Rt with some version of the well-known Kermack-McKendrick model [7,17,30,35].”
MethodGuo, X., Liu, Z., Yang, S., Zhao, Z., Guo, Y., Abudurusuli, G., Zhao, S., Ge, Z., Hu, S., Luo, K., et al. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.01.003
“…have suggested that priority should be given to vaccinating the elderly population against the new coronavirus to reduce the number of seriously ill patients and reduce mortality, and to the young population to reduce the spread of the new coronavirus (Buckner et al., 2021) (Bubar et al., 2021).”
Zou, Y., Lo, W.-C., Ming, W., & Yuan, H. (2023) · medRxiv · doi:10.1101/2023.02.14.23285831
“Incorporating the continuous change of vaccine protection into modelling can also be used to improve previous vaccine dose interval studies [9,10], aiming to optimize vaccine protection.”
BackgroundMethodZhou, Y., Li, Z., Wu, W., Xiao, J., Ma, W., & Zhu, G. (2023) · Epidemiology and Infection · doi:10.1017/s0950268823000274 · Cited by 1
“Many studies have been conducted regarding vaccination evaluation, such as prioritising vaccination for different age groups [7]; predicting the epidemic end time in the USA [8]; estimating the number of infections, hospitalisations and deaths avoided by vaccine [9]; and predicting the end time of Omicron variant [10].”
Analysis of an ongoing epidemic: Advantages and limitations of COVID-19 modeling
Santana-Cibrian, M., Acuña‐Zegarra, M. A., Tocto-Erazo, M. R., & Corona-Moreno, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95064-0.00005-1
SVEAuAdIR model of COVID-19 Transmission
Nisitasari, A., & Rokhman, N. (2023) · IJCCS (Indonesian Journal of Computing and Cybernetics Systems) · doi:10.22146/ijccs.73334
Nakamoto, I. (2023) · medRxiv · doi:10.1101/2023.04.16.23288641
Nakamoto, I. (2023) · medRxiv · doi:10.1101/2023.04.24.23289029
“In this study, I demonstrated the applicability of the revision to the classic EpiEstim and Log-linear method by curtailing the bias on the estimation of basic and effective reproduction numbers [24-30].”
InfluentialComplex Dynamics in the Spread of COVID-19
Contreras, S. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9876
Tovissodé, C. F., & Kakaï, R. G. (2023) · Preprints.org · doi:10.20944/preprints202212.0067.v2
Lim, Y., Ko, Y., Mendoza, R., Mendoza, V. M. P., Lee, J., & Jung, E. (2023) · medRxiv · doi:10.1101/2023.05.24.23290452
“Figure 1 shows the flow diagram of a leaky vaccine model [22].”
BackgroundFine-grained parallel social modelling for analyzing COVID-19 propagation
Martínez, A. C., Isabel, Á. A., Carretero, J., & Singh, D. E. (2023) · Euromicro International Conference on Parallel, Distributed and Network-Based Processing (PDP) · doi:10.1109/pdp59025.2023.00026
“Bubar et al [5] compare five age-stratified prioritization strategies in terms of cumulative incidence, mortality and years of life lost.”
BackgroundJin, A., & Sharifi, H. (2022) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2022.46.007413 · Cited by 1
Efeitos não lineares dos padrões de contatos em estratégias de vacinação
Schulenburg, A. (2022) · doi:10.47328/ufvbbt.2022.619
Analysis of Hybrid Epidemiological-Economic Models of COVID-19 Mitigation Policies
Carrick-Hagenbarth, J., Edlund, E. M., & Mukherjee, A. (2023) · Eastern Economic Journal · doi:10.1057/s41302-023-00256-z
“For example, some recent studies (not part of this analysis) that examined vaccine distribution strategies have shown that the optimal strategy (young first or elderly first) depends on the quantity of vaccines and vaccine effectiveness (Bubar et al. 2021; Matrajt et al. 2021).”
BackgroundSels, J. M. V. L., Bailin, H., Bell, M. R., McCormick-Ell, J., Das, S. B., Roder, A. E., Ghedin, E., McGann, M., Castel, A. D., Prevots, D. R., et al. (2023) · medRxiv · doi:10.1101/2023.11.07.23297422
Shoib, S., Saeed, F., Philip, S., Chandradasa, M., Das, S., de Filippis, R., Yousaf, Z., Ojeahere, M. I., Gad, H. K., Yadivel, R., et al. (2023) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_54_22
“[48] A downside to creating priority groups is that coverage rates are lowered as more resources are spent on the identified category.”
Vaccine Allocation Strategy for Addressing Vaccine-Induced Asymptomatic Infections
Tang, A., Gao, Y., Liu, M., Peng, Y., Liu, J., & Shi, B. (2023) · IEEE/WIC/ACM International Conference on Web Intelligence and Intelligent Agent Technology (WI-IAT) · doi:10.1109/wi-iat59888.2023.00094
Estimating the resultant efficacy of the rollout of multiple vaccines in a population
Improso, H. R. L. D., Sambayan, R. R., Bargo, M. C. R., & Lope, J. E. C. (2024) · AIP conference proceedings · doi:10.1063/5.0183373
Acuña‐Zegarra, M. A., Santana-Cibrian, M., Hernandez-Vela, C. E. R., Mena, R. H., & Velasco‐Hernández, J. X. (2024) · Contemporary mathematics - American Mathematical Society · doi:10.1090/conm/793/15878
Coupled dynamics of the spread of COVID-19, interventions and human behaviour
Iftekhar, E. N. (2024) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10390
Getahun, G. K., Sefefe, H., Shitemaw, T., & Wubete, B. Y. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100481
Mathematical Modelling of COVID-19 with Vaccination, Quarantine and Non-Pharmaceutical Interventions
Mustapha, A., Musa, S. A., Abdullahi, M., & Husseini, A. (2024) · International Journal of Development Mathematics (IJDM) · doi:10.62054/ijdm/0101.12
“The basic reproduction number was established using next-generation method (Bubar 2021).”
MethodLi, M., Zu, J., Zhang, Y., Ma, L., Shen, M., Li, Z., & Ji, F. (2022) · Figshare · doi:10.6084/m9.figshare.19367714
Velasco‐Hernández, J. X. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2104.07793
“So, release of older adults at the same time than younger individuals may increase the IFR because of higher transmission and mortality in the older adults age group [5].”
BackgroundMethodUma estratégia de vacinação Envy-free
Almeida, P. R. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.43.2024.tde-28022024-082900
Duong, K. N. C., Nguyen, D. T., Kategeaw, W., Liang, X., Khaing, W., Visnovsky, L. D., Veettil, S. K., McFarland, M., Nelson, R. E., Jones, B. E., et al. (2024) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2024.100806
Soni, V., Joshi, S., Deep, K., & Pant, M. (2024) · Lecture notes in networks and systems · doi:10.1007/978-981-97-3292-0_62
A Bicriteria Model to Determine Pareto Optimal Pulse Vaccination Strategies
Samanlıoğlu, F., Tabassum, N., Karaca, T. K., & Bilge, A. H. (2024) · Applied Computational Intelligence and Soft Computing · doi:10.1155/2024/5531062
Westerhof, I., de Boer, A. R., Lupattelli, A., Slurink, I. A. L., Zuithoff, N. P. A., Boldea, O., Nordeng, H., Bosdriesz, J. R., Pijpers, F. P., van der Loeff, M. F. S., et al. (2024) · medRxiv · doi:10.1101/2024.09.06.24313189
Faucher, B. (2024) · theses.fr (ABES) · doi:10.70675/ab1b18edz6937z4e65zbea1ze15a0dc75aa4
Atienza-Diez, I., Rodríguez-Maroto, G., Ares, S., & Manrubia, S. C. (2024) · Royal Society Open Science · doi:10.1098/rsos.240753
“Some of these studies used data from sociological studies elaborated in the absence of social contact limitations or, in the best case, implemented such limitations in a phenomenological way, using for instance effective values of the reproduction number in the simulations [12, 14].”
InfluentialIntegrating Metaheuristics and Machine Learning for Wellbeing Management
AlSenani, S., & Bouktif, S. (2024) · Wiley eBooks · doi:10.1002/9781394287024.ch12
Devi, A., & Gupta, P. K. (2025) · Chaos An Interdisciplinary Journal of Nonlinear Science · doi:10.1063/5.0243816
Bioethics of Access to COVID-19 Vaccines
Jaoko, W. G. (2024) · Advancing global bioethics · doi:10.1007/978-3-031-77669-4_2
Metadata
- Authors
- Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B.
- Affiliations
- University of Colorado Boulder (US)
- Harvard University (US)
- University of Chicago (US)
- Corresponding author
- Bubar, Kate M.
- Larremore, Daniel B.
- ORCID
- Venue
- Science
- Published
- 2021-02-26
- Volume
- 371
- Issue
- 6532
- Pages
- 916-921
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963218
- OpenAlex
- W3123021790
- Cited by
- 775
- References
- 45
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 87 · 2023: 109 · 2022: 222 · 2021: 261
- FWCI
- 65.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- University of Chicago (cc-by)
- Funders
- National Institutes of Health (3U24GM132013-02S2)
- Morris-Singer Fund
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine prioritization, SARS-CoV-2, serostatus, serological testing, transmission-blocking vaccine, vaccine inequity, cumulative incidence, mortality, years of life lost, naturally acquired immunity, vaccine supply
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.